NO20016088L - Nervebeskyttende og retinobeskyttende oftalmologiske medisiner - Google Patents

Nervebeskyttende og retinobeskyttende oftalmologiske medisiner

Info

Publication number
NO20016088L
NO20016088L NO20016088A NO20016088A NO20016088L NO 20016088 L NO20016088 L NO 20016088L NO 20016088 A NO20016088 A NO 20016088A NO 20016088 A NO20016088 A NO 20016088A NO 20016088 L NO20016088 L NO 20016088L
Authority
NO
Norway
Prior art keywords
protective
ramiprilat
medicine
visual
acuity
Prior art date
Application number
NO20016088A
Other languages
English (en)
Norwegian (no)
Other versions
NO20016088D0 (no
Inventor
Raouf Rekik
Original Assignee
Raouf Rekik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915359A external-priority patent/FR2794975A1/fr
Application filed by Raouf Rekik filed Critical Raouf Rekik
Publication of NO20016088D0 publication Critical patent/NO20016088D0/no
Publication of NO20016088L publication Critical patent/NO20016088L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
NO20016088A 1999-06-16 2001-12-13 Nervebeskyttende og retinobeskyttende oftalmologiske medisiner NO20016088L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TN99122 1999-06-16
FR9915359A FR2794975A1 (fr) 1999-06-16 1999-12-06 Medicaments opthalmologiques neuro et retino-protecteurs
PCT/FR2000/001679 WO2000076499A2 (fr) 1999-06-16 2000-06-16 Medicaments ophtalmologiques neuro-et retino-protecteurs

Publications (2)

Publication Number Publication Date
NO20016088D0 NO20016088D0 (no) 2001-12-13
NO20016088L true NO20016088L (no) 2002-02-12

Family

ID=26235177

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016088A NO20016088L (no) 1999-06-16 2001-12-13 Nervebeskyttende og retinobeskyttende oftalmologiske medisiner

Country Status (20)

Country Link
US (1) US7049340B1 (de)
EP (1) EP1185255B1 (de)
JP (1) JP2003501461A (de)
AT (1) ATE424819T1 (de)
AU (1) AU6449000A (de)
BR (1) BR0011714A (de)
CA (1) CA2376909A1 (de)
CZ (1) CZ20014516A3 (de)
DE (1) DE60041765D1 (de)
DK (1) DK1185255T3 (de)
ES (1) ES2324200T3 (de)
HU (1) HUP0201478A3 (de)
MA (1) MA26798A1 (de)
MX (1) MXPA01012907A (de)
NO (1) NO20016088L (de)
PL (1) PL352365A1 (de)
SI (1) SI1185255T1 (de)
SK (1) SK18772001A3 (de)
TR (1) TR200103665T2 (de)
WO (1) WO2000076499A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
EP2021000A2 (de) * 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
RU2471454C2 (ru) * 2010-12-14 2013-01-10 Валерий Викторович Педдер Способ лечения дистрофических заболеваний сетчатки глаза
CA2877590A1 (en) * 2012-06-29 2014-01-03 Raouf Rekik Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381850D1 (de) * 1982-12-27 1990-10-04 Schering Corp Pharmazeutische zusammensetzung.
DE3410732A1 (de) * 1984-03-23 1985-09-26 Hoechst Ag, 6230 Frankfurt Methode zur behandlung des glaukoms
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
JPH05306296A (ja) * 1992-04-24 1993-11-19 Marino Forum 21 魚類由来ペプチドとその製法
WO1999036062A1 (en) * 1998-01-16 1999-07-22 Alcon Laboratories, Inc. Topical administration of angiotensin-converting enzyme inhibitors

Also Published As

Publication number Publication date
PL352365A1 (en) 2003-08-25
CA2376909A1 (fr) 2000-12-21
US7049340B1 (en) 2006-05-23
SI1185255T1 (sl) 2009-08-31
AU6449000A (en) 2001-01-02
HUP0201478A2 (hu) 2002-11-28
ATE424819T1 (de) 2009-03-15
SK18772001A3 (sk) 2002-04-04
MA26798A1 (fr) 2004-12-20
DK1185255T3 (da) 2009-07-06
DE60041765D1 (de) 2009-04-23
ES2324200T3 (es) 2009-08-03
EP1185255A2 (de) 2002-03-13
MXPA01012907A (es) 2003-06-24
TR200103665T2 (tr) 2002-10-21
CZ20014516A3 (cs) 2002-05-15
EP1185255B1 (de) 2009-03-11
NO20016088D0 (no) 2001-12-13
HUP0201478A3 (en) 2004-05-28
WO2000076499A2 (fr) 2000-12-21
JP2003501461A (ja) 2003-01-14
BR0011714A (pt) 2002-03-05
WO2000076499A3 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
WO2004028570A3 (en) A method for treating severe tinnitus
JP2019206544A (ja) 次亜塩素酸ナトリウムを含む抗炎症溶液
EP1074258A3 (de) Verfahren und Zusammensetzungen zur Behandlung von Augenerkrankungen und -Zuständen
NO20016088D0 (no) Nervebeskyttende og retinobeskyttende opalmologiske medisiner
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
WO1995016435A3 (en) Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
Bucci Jr et al. Branch retinal artery occlusion secondary to percutaneous transluminal coronary angioplasty.
AU3401093A (en) Therapeutic agent for threatened abortion
Quah et al. A Review of 5 Years' Experience in the Use of Botulinum Toxin A in the Treatment of Sixth Cranial Nerve Palsy at Singapore National Eye Centre
DK0410749T3 (da) Anthocyanidiner til behandling af ophthalmiske sygdomme
RU2000101091A (ru) Способ лечения дистрофических заболеваний сетчатки и зрительного нерва
PL354961A1 (en) Prevention and treatment of diseases associated with blood coagulation
AU2001223953A1 (en) Use of l-carnitine as stabilizing agent of proteins
RU2148972C1 (ru) Способ лечения гемофтальма
RU2077877C1 (ru) Способ лечения сосудистой патологии глаз
WO2003006002A8 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
DE69431430D1 (de) Faktor XIII zur Behandlung von Hautwunden
RU2290191C2 (ru) Способ лечения туберкулезных увеитов
CY1110476T1 (el) Οφθαλμολογικα φαρμακα προστατευτικα του αμφιβληστροειδους τα οποια περιεχουν ραμιπριλη ή ραμιπριλατη
Khare Pyrrolidinomethyltetracycline in cavernous sinus thrombosis
RU2160076C2 (ru) Способ хирургической коррекции миопии и миопического астигматизма высокой степени
RU2002109353A (ru) Способ лимфотропной терапии больных открытоугольной глаукомой с нормализованным внутриглазным давлением
Goldberg Comparison of tropical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma 2001; 10: 414-22
Roberts Antifibrinolytic agents in traumatic hemorrhage
Vazquez Two advances ease burden of CMV treatment

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application